← Browse by Condition
Medical Condition
advanced or metastatic breast cancer
Total Trials
2
Recruiting Now
2
Trial Phases
Phase 2, Phase 1
NCT06201234 Phase 2
Recruiting
Evaluating the Addition of Elacestrant (Oral SERD) to Olaparib (PARP-inhibitor) in Patients With Advanced/Metastatic HR+/HER2- Breast Cancer
Enrollment
176 pts
Location
Germany
Sponsor
GBG Forschungs GmbH
NCT05187832 Phase 1
Recruiting
A Study of AND019 in Women With ER Positive HER2 Negative Advanced or Metastatic Breast Cancer
Enrollment
61 pts
Location
United States
Sponsor
Kind Pharmaceuticals LLC